Affinity Asset Advisors, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001773195
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 90 positions · Total reported value $1.04B · Top-10 concentration 43.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 55.3% · 24 new · 29 cut · 20 exited
Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -12.1% · vs SPY -14.3% · Prev Value $2.08B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -2.2% · vs SPY -4.3% · Latest Value $2.15B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2025 13F filing, Affinity Asset Advisors, LLC disclosed 90 equity positions with a combined reported value of $1.04B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 43.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were VRNA ($66.69M), SPY ($56.29M), XENE ($56.21M). By sector, the heaviest allocations are Health Care 67.3%, Materials 0.4%. Versus the prior quarter, allocation shifted toward Other (+1.5pp) and away from Health Care (-1.4pp).
Versus the prior quarter, Affinity Asset Advisors, LLC opened 24 new positions, trimmed 29 and fully exited 20, a turnover rate of 55.3% of positions. The portfolio's overlap with the prior quarter was 64% of names.
The largest new positions opened in Q3 2025 were SPY ($56.29M), CYTK ($19.24M), SLNO ($13.52M).
Of the 20 positions fully exited versus the prior quarter, the largest were BPMC ($32.05M), AMGN ($11.17M), CRSP ($9.73M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- SPY STATE STR SPDR S&P 500 ETF T · $56.29M
- CYTK CYTOKINETICS INC · $19.24M
- SLNO SOLENO THERAPEUTICS INC · $13.52M
- DNTH DIANTHUS THERAPEUTICS INC · $10.31M
- CLDX CELLDEX THERAPEUTICS INC NEW · $7.76M
- TARS TARSUS PHARMACEUTICALS INC · $7.43M
- SMMT SUMMIT THERAPEUTICS INC · $7.23M
- NTLA INTELLIA THERAPEUTICS INC · $5.18M
Fully Exited (vs previous quarter)
- BPMC BLUEPRINT MEDICINES CORP · prev qtr: $32.05M
- AMGN AMGEN INC · prev qtr: $11.17M
- CRSP CRISPR THERAPEUTICS AG · prev qtr: $9.73M · history
- INZY INOZYME PHARMA INC · prev qtr: $7.00M
- AXSM AXSOME THERAPEUTICS INC. · prev qtr: $5.22M
- RAPP RAPPORT THERAPEUTICS INC · prev qtr: $2.27M
- THRD THIRD HARMONIC BIO INC · prev qtr: $2.01M
- CAPR CAPRICOR THERAPEUTICS INC · prev qtr: $1.74M
Insider Transactions (Form 4)
Latest Affinity Asset Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Affinity Asset Advisors, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 108 US equity positions with a combined value of $2.08B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-120744 (status: Approved), registered 2021-04-09
- Regulatory AUM (Form ADV): $2.45B as of 2026-07-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
- Website: affinityadv.com
Portfolio Structure
- 108 positions · $2.08B reported value (Q2 2026)
- Top 10 holdings = 41.7% of reported value
- Largest position: ROIV (ROIVANT SCIENCES LTD) at 6.4%
- Average position size: $19.25M
Sector Tilt
- Health Care 87.6%
- Financials 1.3%
- Materials 0.3%
- (classified holdings cover 89% of value)
Quarterly Activity
- Q2 2026: 19 new, 34 added, 31 reduced, 12 exited
- 24 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
625.00K | $66.69M | 6.43% | Add | |
| 2 |
|
84.49K | $56.29M | 5.43% | New | |
| 3 |
|
1.40M | $56.21M | 5.42% | Add | |
| 4 |
|
115.00K | $52.75M | 5.09% | Add | |
| 5 |
|
1.17M | $46.62M | 4.50% | Add | |
| 6 |
|
500.00K | $41.05M | 3.96% | Add | |
| 7 |
|
1.25M | $37.50M | 3.62% | Add | |
| 8 |
|
384.42K | $33.24M | 3.21% | Reduce | |
| 9 |
|
360.00K | $30.56M | 2.95% | Add | |
| 10 |
|
205.00K | $29.52M | 2.85% | Reduce | |
| 11 |
|
750.00K | $28.44M | 2.74% | Reduce | |
| 12 |
|
1.40M | $28.28M | 2.73% | Hold | |
| 13 |
|
285.77K | $26.91M | 2.59% | Add | |
| 14 |
|
1.11M | $26.85M | 2.59% | Add | |
| 15 |
|
3.87M | $25.70M | 2.48% | Add | |
| 16 |
|
2.80M | $25.62M | 2.47% | Add | |
| 17 |
|
1.42M | $23.79M | 2.29% | Add | |
| 18 |
|
2.10M | $19.74M | 1.90% | Reduce | |
| 19 |
|
350.00K | $19.24M | 1.85% | New | |
| 20 |
|
959.18K | $18.45M | 1.78% | Add | |
| 21 |
|
300.00K | $17.51M | 1.69% | Add | |
| 22 |
|
2.10M | $15.37M | 1.48% | Add | |
| 23 |
|
220.60K | $14.65M | 1.41% | Reduce | |
| 24 |
|
200.00K | $13.52M | 1.30% | New | |
| 25 |
|
1.01M | $12.79M | 1.23% | Add | |
| 26 |
|
310.00K | $12.71M | 1.23% | Reduce | |
| 27 |
|
3.92M | $12.20M | 1.18% | Reduce | |
| 28 |
|
800.00K | $12.10M | 1.17% | Add | |
| 29 |
|
262.10K | $10.31M | 0.99% | New | |
| 30 |
|
3.00M | $9.81M | 0.95% | Add | |
| 31 |
|
4.29M | $9.34M | 0.90% | Add | |
| 32 |
|
967.62K | $8.94M | 0.86% | Hold | |
| 33 |
|
303.33K | $8.81M | 0.85% | Reduce | |
| 34 |
|
400.00K | $8.19M | 0.79% | Hold | |
| 35 |
|
7.00M | $7.93M | 0.76% | Hold | |
| 36 |
|
275.00K | $7.82M | 0.75% | Hold | |
| 37 |
|
300.00K | $7.76M | 0.75% | New | |
| 38 |
|
3.60M | $7.67M | 0.74% | Add | |
| 39 |
|
125.00K | $7.43M | 0.72% | New | |
| 40 |
|
350.00K | $7.23M | 0.70% | New | |
| 41 |
|
2.45M | $6.69M | 0.65% | Add | |
| 42 |
|
79.48K | $6.49M | 0.63% | Add | |
| 43 |
|
150.00K | $6.20M | 0.60% | Hold | |
| 44 |
|
1.27M | $5.52M | 0.53% | Add | |
| 45 |
|
250.00K | $5.39M | 0.52% | Reduce | |
| 46 |
|
1.50M | $5.36M | 0.52% | Add | |
| 47 |
|
300.00K | $5.18M | 0.50% | New | |
| 48 |
|
300.00K | $4.84M | 0.47% | New | |
| 49 |
|
100.00K | $4.67M | 0.45% | New | |
| 50 |
|
1.13M | $4.65M | 0.45% | Add | |
FAQ
What did Affinity Asset Advisors, LLC buy in 2025-Q3?
In its 2025-Q3 13F filing, Affinity Asset Advisors, LLC reported 90 equity positions worth $1.04B in aggregate; its largest disclosed positions were VRNA ($66.69M), SPY ($56.29M), XENE ($56.21M).
How large is Affinity Asset Advisors, LLC's portfolio?
Affinity Asset Advisors, LLC reported $1.04B of long equity holdings across 90 positions as of 2025-Q3. Top-10 holdings account for 43.4% of reported value.
What is Affinity Asset Advisors, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.